Name: Latest research reports of Sun Pharmaceutical Industries Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Sun Pharmaceutical Industries Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
	01 Feb 2025	Sun Pharmaceutical	BOB Capital Markets Ltd. Reco Target	1664.90	2086.00	1742.20 (-4.44%)	25.29	Buy	pdf post cache	Broker Report Sun Pharma (BUY): Strong performance to continue BOB Capital Markets Ltd. Domestic sales grew by 14% in Q3FY25 driven partially by volume/new launches and price hikes. Strong domestic sales growth to continue pdf Copy Link Share on Share on Share on Share on Alert
	01 Feb 2025	IndusInd Bank	BOB Capital Markets Ltd. Target	814.35	1190.00	1009.40 (-19.32%)	46.13	Buy	pdf post cache	Broker Report Indusind Bank (BUY): Missed on most metrics BOB Capital Markets Ltd. Subdued quarter with moderate growth in advances and deposits, MFI book under stress pdf Copy Link Share on Share on Share on Share on Alert
	01 Feb 2025	Marico	BOB Capital Markets Ltd.	703.05	695.00	694.20 (1.27%)	Target met	Hold	pdf post cache	Broker Report Marico (HOLD): Managing inflation BOB Capital Markets Ltd. Compared to consensus, 3QFY25 sales were 2% lower (1% below our estimate) while EBITDA was 1% pdf Copy Link Share on Share on Share on Share on Alert
	01 Feb 2025	Bandhan Bank	BOB Capital Markets Ltd. Target	169.02	187.00	151.39 (11.65%)	10.64	Buy	pdf post cache	Broker Report Bandhan Bank (BUY): Other income aids PPOP; MFI stress persists BOB Capital Markets Ltd. PPOP aided by one-offs in other income, payouts under CGFMU and Assam Microfinance relief scheme pdf Copy Link Share on Share on Share on Share on Alert
	01 Feb 2025	Nestle	BOB Capital Markets Ltd. Target	2397.50	2470.00	2327.20 (3.02%)	Target met	Hold	pdf post cache	Broker Report Nestle India (HOLD): Managing profits amidst inflation BOB Capital Markets Ltd. NEST continues to manage profits amidst inflation in cocoa and coffee. Wheat and palm have also turned inflationary pdf Copy Link Share on Share on Share on Share on Alert
	31 Jan 2025	eClerx Services	BOB Capital Markets Ltd.	3502.20	3727.00	3058.15 (14.52%)	6.42	Buy	pdf post cache	Broker Report eClerx Services (BUY): Should be among the faster growing Tier-2 players BOB Capital Markets Ltd. 3QFY25 broadly in line. A margin miss. Expect 4Q QoQ growth to be stronger. Expect low teen USD revenue growth in FY25-FY27. pdf Copy Link Share on Share on Share on Share on Alert
	31 Jan 2025	Voltas	BOB Capital Markets Ltd. Target	1229.40	1400.00	1260.85 (-2.49%)	Target met	Hold	pdf post cache	Broker Report Voltas (HOLD): Revenue in line with estimates, PAT sees lag BOB Capital Markets Ltd. Topline grew 18% YoY in Q3; EBITDA margin expanded 530bps YoY fueled by better cost efficiencies pdf Copy Link Share on Share on Share on Share on Alert
	31 Jan 2025	Ajanta Pharma	BOB Capital Markets Ltd. Target	2586.40	2288.00	2694.45 (-4.01%)	11.54	Sell	pdf post cache	Broker Report Ajanta Pharma (SELL): Entering newer therapies to result in higher costs BOB Capital Markets Ltd. AJP reported in-line earnings, sales were 3.6% below estimates, while EBITDA/PAT reported 1%/3% above our estimates pdf Copy Link Share on Share on Share on Share on Alert
	31 Jan 2025	Dabur	BOB Capital Markets Ltd. Reco Target	491.85	578.00	529.85 (-7.17%)	17.52	Hold	pdf post cache	Broker Report Dabur India (HOLD): Competition and inflation BOB Capital Markets Ltd. Competitive intensity has increased in the domestic business and Dabur is doing retailer discounts to maintain market share pdf Copy Link Share on Share on Share on Share on Alert
	31 Jan 2025	Tata Consumer	BOB Capital Markets Ltd. Target	1124.40	1175.00	1024.65 (9.74%)	Target met	Buy	pdf post cache	Broker Report Tata Consumer Products (BUY): Staying rational BOB Capital Markets Ltd. Tea inflation recovery prospects have improved as higher pricing has come through earlier than expected pdf Copy Link Share on Share on Share on Share on Alert
more loading

BOB Capital Markets Ltd. Broker Research reports

Latest broker research reports from BOB Capital Markets Ltd. buy, sell, hold, neutral recommendations along with share price targets forecast and upside.

Sun Pharma (BUY): Strong performance to continue

Indusind Bank (BUY): Missed on most metrics

Marico (HOLD): Managing inflation

Bandhan Bank (BUY): Other income aids PPOP; MFI stress persists

Nestle India (HOLD): Managing profits amidst inflation

eClerx Services (BUY): Should be among the faster growing Tier-2 players

Voltas (HOLD): Revenue in line with estimates, PAT sees lag

Ajanta Pharma (SELL): Entering newer therapies to result in higher costs

Dabur India (HOLD): Competition and inflation

Tata Consumer Products (BUY): Staying rational

Advisor Screeners